natamycin  (MedChemExpress)

Journal: Pathogens

Article Title: Malassezia pachydermatis Acquires Resistance to Polyenes in the Laboratory Model

doi: 10.3390/pathogens14111162

Figure Lengend Snippet: Comparison of the chemical structures of nystatin and natamycin [ , ].

Article Snippet: In the next step, 10 μL of inoculum was added to 1.5 mL Eppendorf tubes containing 1 mL of liquid YPD medium supplemented with either natamycin (Merck Life Science, Darmstadt, Germany) or nystatin (Merck Life Science, Darmstadt, Germany) across a concentration gradient ranging from 0 to 90 μg/mL in 2 μg/mL increments.

Techniques: Comparison

Journal: Pathogens

Article Title: Malassezia pachydermatis Acquires Resistance to Polyenes in the Laboratory Model

doi: 10.3390/pathogens14111162

Figure Lengend Snippet: Trend lines of MIC value changes for nystatin and natamycin in individual M. pachydermatis strains (only those that survived until the end of the experiment) over 105 weekly passages on antifungal-supplemented media (4 μg/mL for nystatin and 8 μg/mL for natamycin).

Article Snippet: In the next step, 10 μL of inoculum was added to 1.5 mL Eppendorf tubes containing 1 mL of liquid YPD medium supplemented with either natamycin (Merck Life Science, Darmstadt, Germany) or nystatin (Merck Life Science, Darmstadt, Germany) across a concentration gradient ranging from 0 to 90 μg/mL in 2 μg/mL increments.

Techniques:

Journal: Pathogens

Article Title: Malassezia pachydermatis Acquires Resistance to Polyenes in the Laboratory Model

doi: 10.3390/pathogens14111162

Figure Lengend Snippet: Trend lines of MIC value changes for nystatin and natamycin in Malassezia pachydermatis strains across successive passages during experimental modification of antibiotic sensitivity. Statistically significant differences compared to the initial state of * nystatin and # natamycin, p < 0.05, ANOVA, post hoc Tukey’s HSD test.

Article Snippet: In the next step, 10 μL of inoculum was added to 1.5 mL Eppendorf tubes containing 1 mL of liquid YPD medium supplemented with either natamycin (Merck Life Science, Darmstadt, Germany) or nystatin (Merck Life Science, Darmstadt, Germany) across a concentration gradient ranging from 0 to 90 μg/mL in 2 μg/mL increments.

Techniques: Modification